to reach a maximum at 7.8 days (288 + 44 ~1) with a biexponential decline to 147 f 6 ~1 at 70 days. The cumulative EHDP released in vitro after 70 days was 4.2 + 0.6% (4.8 k 0.7 mg) compared to 15.7 i 3.2% (18.1 +_ 3.7 mg) in vivo (subcutaneously in 3 week-old, male, CD rats) over 21 days. The release rate of EHDP from the reservoirs was not a zero-order process. Reservoir administration of EHDP effectively inhibited pericardial BHV-CALC in 21-day subdermal explants (Ca*+ = 4.5 + 1.4 ng Ca' +/mg tissue; control, Ca*+ = 120 + 13 pg Ca*+/mg tissue) without diphosphonate-related untoward effects at a dose of approx. 3 mg/kg _ per day.
Calcification
(CALC) of bioprosthetic heart valves (BHVs) fabricated from either glutaraldehyde-pretreated bovine pericardial tissue or porcine aortic valves is the most frequent cause of clinical failure of these devices. Previous studies have demonstrated that calcification is inhibited by diphosphonate compounds released into the vicinity of bioprosthetic tissue implanted subcutaneously in rats. Controlled release of the anticalcification agent ethanehydroxy diphosphonate (EHDP), as a 1:l mixture of Na,EHDP and CaEHDP from cylindrical polyurethane (PU) reservoirs (o.d. = 0.36 cm, id. = 0.33 cm, length = 4 cm) fabricated by solvent casting was assessed in vitro and in viva. The diffusivity (D), determined independently using standard diffusion cells, for ionic EHDP diffusion across the PU membrane was 1.2 X 10mio cm'/s. Volume influx of buffer into the reservoirs in vitro was observed experimentally to reach a maximum at 7.8 days (288 + 44 ~1) with a biexponential decline to 147 f 6 ~1 at 70 days. The cumulative EHDP released in vitro after 70 days was 4.2 + 0.6% (4.8 k 0.7 mg) compared to 15.7 i 3.2% (18.1 +_ 3.7 mg) in vivo (subcutaneously in 3 week-old, male, CD rats) over 21 days. The release rate of EHDP from the reservoirs was not a zero-order process. Reservoir administration of EHDP effectively inhibited pericardial BHV-CALC in 21-day subdermal explants (Ca*+ = 4.5 + 1.4 ng Ca' +/mg tissue; control, Ca*+ = 120 + 13 pg Ca*+/mg tissue) without diphosphonate-related untoward effects at a dose of approx. 3 mg/kg _ per day.
Introduction
Pathologic calcification is the primary process leading to sterile degeneration of bioprosthetic heart valves (Milan0 et al., 1984; Schoen and Levy, 1984; Schoen and Hobson, 1985; Schoen, 1987) fabricated from either glutaraldehyde-pretreated porcine aortic valves or bovine pericardium. Dysfunction of the calcified bioprosthetic heart valve typically results from either stenosis or secondary calcific tearing of the leaf-lets. Pathologic deposition of calcium phosphate crystals is also important in other cardiovascular diseases such as arteriosclerosis (Levy et al.. 1983a ). myocardial infarction (Hagler et al.. 1981) valvular heart disease (Levy et al., 1980) , and mineralization of the elastomeric blood-contacting surfaces of artificial heart devices (Pierce et al., 1980) . Despite the prevalence of cardiovascular calcification, the pathophysiology of BHV calcification is incompletely understood (Schoen et al., 1985a (Schoen et al., , 1988 . Recently, much research has been directed at developing satisfactory means for its prevention.
The calcification of bioprosthetic heart valves has been extensively investigated experimentally. Animal models utilized in studying BHV-CALC have involved orthotopic valve replacements or conduit-mounted valves in sheep and calves (Barnhart et al., 1982a; Levy et al., 1983b; Thubrikar et al., 1983 : Gallo et al.. 1987 . and subcutaneous implants in mice (Levy et al.. 1983~) . rats (Levy et al., 1983d.e) . and rabbits (Fishbein et al., 1982) . Many of the pathologic findings from long-term clinical implants are simulated by the subcutaneous and circulatory animal models (Fishbein et al., 1982; Levy et al.. 1983c ,d: Barnhart et al., 1982b Arbustini et al., 1984; Schoen et al., 1985b) . Ethanehydroxy diphosphonate (EHDP) has been shown to inhibit effectively experimental BHV calcification (Levy et al.. 1985b,c) . However. subcutaneous administration of EHDP to rats at doses greater than 15 mg/kg per day has been shown to be associated with adverse effects on overall somatic growth. bone development. and serum Ca' + levels (Levy et al., 1987) . Nevertheless, controlled release of EHDP from a variety of polymeric matrices directly into BHV tissue prevented BHV-CALC using minimal local doses and avoided adverse effects (Levy et al.. 1985b ,c: Golomb et al., 1986a ,b. 1987 .
The purpose of the present study was to fabricate controlled release polyurethane reservoirs and evaluate their in vitro release profiles and in vivo efficacy and function using the rat subdermal model of bioprosthetic tissue calcification. (1:l) were incubated at 37°C in 24 ml of a physiologic buffer (0.05 M Hepes adjusted to 0.15 M with NaCl, pH 7.4) with constant stirring (150 rpm) by using an orbital shaker (Lab Line, Melrose Park, CA). At specified time points over the 70 day in vitro release period, reservoirs were removed from the buffer, gently washed with distilled water to remove any radioactive drug solution adhering to the surface of the reservoir, and then placed in 24 ml of fresh buffer. A 5 ml aliquot of the receptor phase containing solubilized Na,['4C]EHDP was removed, combined with 15 ml of the scintillation fluor and then counted for 14C activity on a Beckman liquid scintillation counter (model no. 3801, Berkeley, CA). The release profiles of Na,['4C]EHDP from the controlled release PU reservoirs were expressed as the cumulative % Na,['4C]EHDP released vs time.
Diffusion studies
The value of D for [14C]EHDP diffusion across a 150 pm thick PU film was determined using standard diffusion cells at 37" C with constant stirring. The receptor solution was a physiologic buffer (see above) preserved with 0.5% sodium azide. Periodically, samples of the receptor phase were removed, counted for 14C activity in a liquid scintillation counter and the % EHDP diffused calculated as a function of time.
Reservoir volume influx studies
Identical drug-loaded reservoirs (see above) were also assessed in vitro for volume influx of buffer during the 70 day release period. Reservoirs were removed from the buffer at regular intervals and the exterior surface blotted dry of surface adhering buffer. The reservoirs were then weighed on an analytical balance and the resulting weights compared to the initial preincubation weight of the drug-loaded reservoir to calculate the amount (volume) of buffer imbibed.
Rat subdermul studies
Prior to implantation, 10 reservoirs were allowed to release EHDP into a physiologic buffer (see above) for 6 days (approx. 2 X t,,,) to ensure that release of EHDP from the reservoirs was proceeding at a constant rate (zero-order) based on preliminary results of the EHDP diffusion studies. Ten rats (3-week-old, male CD strain, Charles River Labs, Wilmington, MA) were implanted subcutaneously with drug-loaded reservoirs on the dorsal side adjacent to a 3.0 x 0.9 cm2 strip of glutaraldehyde-pretreated, bovine pericardial
tissue. An additional 7 rats were implanted as above with BHV tissue adjacent to empty PU reservoirs. Reservoirs and BHV tissue were explanted at 21 days. A representative section of the BHV tissue was immediately fixed in a cacodylate-buffered 2.5% glutaraldehyde-2% paraformaldehyde solution buffered at pH 7.2 (Karnovsky, 1965) for 24 h and then dehydrated in graded ethanol solutions (Levy et al., 1985b) prior to embedding in glycolmethylmethacrylate (JB-4, Polysciences, Warrington, PA). Sections (2-3 pm) were stained with hematoxylin and eosin for overall morphologic analyses and Von Kossa's reagent for calcium phosphate (Levy et al., 1985b) . The remaining portion of each piece of BHV tissue was prepared for quantitative analysis of calcium using atomic absorption spectroscopy (Levy et al., 1980 (Levy et al., , 1983d .
Explanted reservoirs were dried at 100°C for 12 h, opened, and the luminal contents removed as a dry pellet. Each cylindrical, rod-shaped pellet was dissolved in 20 ml of deionized water, the solution sonicated (Branson sonifier, model 250, Shelton, CN) and then sampled (5 ml) to determine 14C activity.
All data were expressed as the mean -+ standard error of the mean (SE). The in vitro release and the diffusion studies expressed the mean cumulative percentage of [t4C]EHDP released or diffused, respectively.
Comparisons of means were performed using the Student's t-test. Polyexponential equations used to predict the time course for buffer influx into the reservoirs, amount of drug released from the reservoirs, and decrease in the value of the permeability (DK) of MPU-5 to
were determined according to a nonlinear least-squares regression routine (Bolt et al., 1984) . Initial parameter estimates for the nonlinear fitting routine were obtained graphically via the method-of-residuals.
Results and Discussion
The present study has successfully demonstrated the fabrication and characterization of EHDP controlled release reservoirs. EHDP delivery was characterized in vitro and in vivo and the efficacy of this novel reservoir system was demonstrated in a rat subdermal calcification model.
The value of D was calculated with Eqn. 1:
where fiag denotes the lag-time (s) and I is the polymer membrane thickness (cm). Eqn. 1 assumes that a steady state has been achieved for a constant-activity reservoir device ( Fig. 1) (Baker, 1987) . The lag-time (3.58 days) for EHDP diffusion through the MPU-5 membrane (0.015 cm) was experimentally determined by back extrapolation to the x-axis of the steady-state portion of the curve illustrated in Fig. 1 . Thus, the value of the apparent D was determined to be 1.2 X lo-"' cm2/s. (Fig. 2) . Following 23 h of in vitro release, approx. 170 & 10 ~1 of physiologic buffer (approx. l/2 the reservoir's calculated internal volume) had been imbibed.
Continual uptake of fluid to 7.8 days was observed experimentally, whereupon the volume of fluid inside the reservoir began to decrease in a biexponential fashion for the duration of the in vitro release period. The internal volume of the reservoir as a function of time was estimated as the sum of the internal volume of the empty reservoir and the volume of buffer imbibed in excess (net buffer imbibed, Fig. 2 ) of the volume required for dissolution of the Na:EHDP and Fig. 2 . If it is assumed that bulk flow of buffer into the cylindrical reservoir caused the reservoir to expand in a uniform, cylindrical manner, then it should be possible to quantitate the surface area (A) of the reservoir as a function of time knowing only the time-dependent internal volume of the reservoir. Theoretically, the surface area of the reservoir available for drug transport should reach a maximum at the same time the volume of buffer imbibed described by the t~exponential fit reaches a maximum, i.e., at 8.8 days.
In vitro release of ['4C]EHDP
The percent of [r4C]EHDP delivered in vitro can be noted in Fig. 3 and Table 2 . As a result of the rapid and extensive influx of buffer into the reservoirs at early time points, the continual loss of drug to the bulk receptor phase, and dilution of remaining drug by imbibed buffer, the internal drug concentration decreased with time. Thus, first-order release behavior for ]'4C]EHDP was observed (Fig. 3) and a classical analysis for a cylindrical reservoir having an internal drug solution of nonconstant thermodynamic activity was employed through use of Eqn. 2 (Baker, 1987):
where M(t) and M, denote the amount of [14C]EHDP released at time t and initially contained in the reservoir, respectively, t is time (s), A is the surface area of the reservoir (cm2), D is the diffusion coefficient of ['4C]EHDP (cm'/s), K is the partition coefficient (C,,,,,/C,,,,,) , I is the membrane thickness (cm), and V is the internal volume of the reservoir (cm3). Eqn. 2 assumed that A, D, K, V, and I are constant.
However, 
Recognizing, from geometrical considerations. that A/V' in Eqn. 3 is equal to 4/dia,,, and defining P(r) = D( t)K(t), the left-hand-side of Eqn. 3 can be set equal to {[4P(t)]/[dia,,,(t)l(t)]}dt. Solving the resulting expression for P(t) yields Eqn. 4 where I(t) is assumed to be constant (0.015 cm) throughout the in vitro release period.
The slope d[ M( t)/M,]/dt
was determined from the release data shown in Fig. 3 at each time point. The time-dependent diameter of the reservoir was calculated from the dimensional changes based on the internal volume of the empty reservoir and the volume of buffer imbibed (Table  1) assuming the reservoir expanded in a uniform, cylindrical manner. Thus, the time-dependent permeability, P(r), of the polyurethane test membrane to EHDP was calculated by using Eq. 4.
The calculated values of the mean permeability of the solvent-cast polyurethane reservoirs to EHDP using Eqn. 4 are shown in Fig. 4 . The value of the permeability decreases throughout the 70-day in vitro release period and may be described by a biexponential equation with preexponential coefficients and characteristic time constants shown in Table 1 .
Since the partition coefficient. K = [ "'CIEHD-P mcnr,+' ] " WHDP,,,,, . was independently determined by the solution depletion method (Zentner et al., 1978a) to have a value of 0.53 ir 0.04, the value of the diffusion coefficient, II. for ['4C]EHDP transport across MPU-5 was calculated ( D = DK/K ) as a function of time assuming that K was constant throughout the 70-day in vitro release period. However, it should be noted that the value of D calculated as such is only an estimate of the true diffusivity due to a potentially time-dependent value of K. As expected with division by a constant. the value of D plotted against time yields the same overall time-dependent profile as the value of P with preexponential coefficients and characteristic time constants listed in Table 1 .
Previous research (Lyman, 1964: Lyman and Kim, 1973a,b) has shown that solutes permeate polyether urethanes by a solution-diffusion or partition mechanism.
This type of solute permeation is characterized by dissolution of the soiute in the membrane followed by diffusion along and between the polymer segments that make up the membrane structure (Zentner et al., 197Xb) . The physical-chemical properties of the solute and the polyether urethane membrane play a major role in determining the membrane permeabiIity with the solution-diffusion model (Zentner, 1978b) . Interactions between the solute and the polymer segments of the membranes can greatly influence the value of the diffusion coefficient (Zentner, 1978b) .
The time-dependent nature of P in the present study would suggest that initially, buffer was imbibed with a concomitant rise in the osmotic-induced internal pressure. During the rapid reservoir swelling phase (first 7 days), the high osmotic-induced pressure inside the reservoirs appeared to cause a 'burst-effect' of EHDP through the reservoir membrane. Thereafter, the ionic strengths of both solutions (internal drug solution and external receptor phase) potentially approached an equilibrium value. This may account for the subsequent reduction in the mean value of the calculated permeability.
EHDP may also form insoluble precipitates with components of the HEPES buffer or with polyurethane impurities. Assuming drug precipitation occurs in the lumen of the reservoir following approx. 7 days of in vitro release, the reservoir volume would then decrease to compensate for the loss of ions. Changes in osmotic pressure and drug concentration in the lumen of the reservoir would appear to play an important role in affecting the value of D, and hence, P. Changes in the internal volume, osmotic pressure, drug concentration, and membrane thickness could all affect the value of D, since it is well documented that concentration, pressure, temperature, solvent properties, and the chemical nature of the diffusant may all affect the value of D (Martin et al., 1983; Cussler, 1984; Flynn et al., 1974) .
In vivo efficacy of EHDP delivered by reservoirs
Reservoirs allowed to release [14C]EHDP in vitro for 6 days prior to implantation into rats delivered 2.9 ) 0.4% (3.3 f 0.5 mg) of EHDP. The EHDP released in vivo over 21 days was 15.7 i 3. 2% (18.1 & 3.7 mg) . However, the greater release of EHDP in vivo (15.7 f 3.2%) as compared to in vitro after 70 days (4.2 + 0.6%) was possibly due to movement induced flexing and bending of the reservoir in the rat subdermal model coupled with possible hydrolytic degradation and subsequent microscopic cracking of the polyurethane membrane (Smith et al., 1987) . Constant bending and flexing of the reservoirs in vivo may have caused slight leakage of the saturated Na,EHDP solution from the sealed ends of the device.
EHDP administered by daily subcutaneous injections to rats is known to be associated with disturbed bone growth and altered serum calcium levels at doses exceeding 15 mg/kg per day (Levy et al., 1987) . In the present study, complete inhibition of BHV-CALC (Table 2 ) was observed at an overall dosage of 3.0 mg/kg per day by local, reservoir-based administration of EHDP. Morph@ logical exa~nation revealed that pericardial tissue implanted without reservoirs and that implanted adjacent to empty reservoirs had diffuse mineralization with a morphology similar to that noted in previous studies (Golomb et al., 1986a; Johnston et al., 1988 By limiting the area available for solvent influx, the present reservoir system has the potential for zero-order release of EHDP. The polyurethane reservoirs might be engineered in such a way as to connect the lumen of the reservoir to a water-impermeable, biocompatible cannula that would lead to a percutaneous access device (PAD) situated subcutaneously.
The reservoir could be refilled following drug exhaustion by a standand needle injection of a saturated solution of EHDP into a conveniently located PAD which had previously been implanted subcutaneously.
A refillable reservoir system might also enhance therapeutic efficacy when used in combination with EHDP containing matrices or osmotically driven pump systems. In addition. the possibility of further enhancing therapeutic benefit by combining EHDP drug delivery devices (refillable reservoirs. matrices, osmotic pumps. etc.) with BHV tissue pretreatment strategies also exists. The combination of treatment strategies would assure both short-and long-term release of EHDP to inhibit BHV CALC.
Refillable reservoir systems could be used for treating other cardiovascular diseases. A variety of cardiovascular drugs could be delivered at a constant rate by using this system. Those compounds less water-soluble than EHDP would be expected to permeate the reservoir membrane more slowly. result in less solvent/plasma uptake. and thereby. result in a more protracted zero-order release profile.
Conclusions
Based on the results of the present study. n Mitrathane or other comparable medical-grade polyurethanes might be suitable rate-limiting membranes for use in a reservoir device containing Na-CaEHDP.
Further sustained release of EHDP is possible by exploiting the low aqueous solubility of CaEHDP (Nash, 1984; Golomb et al.. 19X7) . Additional strategies to modify EHDP release rate would be varying either the total surface area available for solvent influx or the hydrophilicity (ratio of polyethylene glycol/urethane segments) of the copolymer.
Interaction of the EHDP anion with the polymer membrane used in the present study may contribute to a time-dependent diffusion coefficient for EHDP transport. Changes in the internal osmotic pressure, drug concentration.
and 
